In BC, oncogenic TP53 mutations in the DNA-binding domain from codon sequences 102 to 292 are related to poor prognosis compared to wild-type TP53, which is associated with better clinical outcome in BC [24]. This evidence concerns the gene TP53 and breast cancer.